Esketamine superior to extended-release quetiapine with respect to remission at week 8
By Elana Gotkine HealthDay Reporter
THURSDAY, Oct. 5, 2023 (HealthDay News) — For patients with treatment-resistant depression, esketamine nasal spray is superior to extended-release quetiapine with respect to remission at week 8, according to a study published in the Oct. 5 issue of the New England Journal of Medicine.
Andreas Reif, M.D., from Goethe University Hospital in Frankfurt, Germany, and colleagues conducted an open-label phase 3b randomized, active-controlled trial involving patients with treatment-resistant depression. Participants were randomly assigned to receive flexible doses of esketamine nasal spray (336 patients) or extended-release quetiapine (340 patient) both in combination with a selective serotonin reuptake inhibitor or a serotonin-norepinephrine reuptake inhibitor. The primary end point was remission, defined as a score of 10 or less on the Montgomery-Ã…sberg Depression Rating Scale (MADRS), at week 8.
The researchers found that more patients in the esketamine group versus the quetiapine group had remission at week 8 (27.1 versus 17.6 percent) and had no relapse through 32 weeks after remission at week 8 (21.7 versus 14.1 percent). The percentage of patients with remission, the percentage with a treatment response, and the change in the MADRS score from baseline favored esketamine over 32 weeks of follow-up.
“These results show the superiority of esketamine nasal spray to extended-release quetiapine with respect to the primary goal of antidepressant treatment in patients with a poor prognosis, in whom treatment goals are rarely met,” the authors write.
The study was funded by Janssen, the manufacturer of esketamine nasal spray.
Editorial (subscription or payment may be required)
Copyright © 2023 HealthDay. All rights reserved.